[go: up one dir, main page]

MA23608A1 - Forme de dosage ii d'unite multiple en comprime - Google Patents

Forme de dosage ii d'unite multiple en comprime

Info

Publication number
MA23608A1
MA23608A1 MA23947A MA23947A MA23608A1 MA 23608 A1 MA23608 A1 MA 23608A1 MA 23947 A MA23947 A MA 23947A MA 23947 A MA23947 A MA 23947A MA 23608 A1 MA23608 A1 MA 23608A1
Authority
MA
Morocco
Prior art keywords
dosage form
tablet unit
multiple tablet
formulation
alkaline salt
Prior art date
Application number
MA23947A
Other languages
English (en)
Inventor
Pontus John Arvid Bergstrand
Kurt Ingmar Lovgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA23608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of MA23608A1 publication Critical patent/MA23608A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA23947A 1994-07-08 1995-07-06 Forme de dosage ii d'unite multiple en comprime MA23608A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402431A SE9402431D0 (sv) 1994-07-08 1994-07-08 New tablet formulation

Publications (1)

Publication Number Publication Date
MA23608A1 true MA23608A1 (fr) 1996-04-01

Family

ID=20394685

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23947A MA23608A1 (fr) 1994-07-08 1995-07-06 Forme de dosage ii d'unite multiple en comprime

Country Status (36)

Country Link
US (1) US5753265A (fr)
EP (3) EP0723437B1 (fr)
JP (2) JPH09502741A (fr)
KR (1) KR100384961B1 (fr)
CN (2) CN1152671C (fr)
AT (1) ATE275396T1 (fr)
AU (1) AU695971B2 (fr)
BR (2) BR9506028A (fr)
CA (2) CA2170644C (fr)
CZ (1) CZ294380B6 (fr)
DE (1) DE69533470T2 (fr)
DK (1) DK0723437T3 (fr)
EE (1) EE03292B1 (fr)
ES (1) ES2227556T3 (fr)
FI (2) FI122016B (fr)
HK (1) HK1008298A1 (fr)
HU (2) HU9600572D0 (fr)
IL (2) IL114449A0 (fr)
IS (3) IS4326A (fr)
MA (1) MA23608A1 (fr)
MY (1) MY114388A (fr)
NO (2) NO960949L (fr)
NZ (1) NZ289949A (fr)
PL (2) PL313389A1 (fr)
PT (1) PT723437E (fr)
RU (2) RU2538511C2 (fr)
SA (1) SA95160092B1 (fr)
SE (1) SE9402431D0 (fr)
SI (1) SI0723437T1 (fr)
SK (1) SK283841B6 (fr)
TN (1) TNSN95076A1 (fr)
TR (2) TR199500825A2 (fr)
TW (1) TW421599B (fr)
UA (1) UA47390C2 (fr)
WO (2) WO1996001625A1 (fr)
ZA (2) ZA955547B (fr)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DK0723436T3 (da) * 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
DK1092434T3 (da) * 1995-09-21 2004-07-26 Pharma Pass Ii Llc Hidtil ukendt sammensætning indeholdende lansoprazol og fremgangsmåde til fremstilling deraf
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
CA2294117A1 (fr) * 1997-07-03 1999-01-14 Dupont Pharmaceuticals Company Imidazopyrimidines et imidazopyridines utiles pour traiter des troubles neurologiques
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6602522B1 (en) * 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
ES2362418T3 (es) * 1997-12-08 2011-07-05 Nycomed Gmbh Nueva forma de supositorio que comprende un compuesto activo ácido-lábil.
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ATE348601T1 (de) 1998-05-18 2007-01-15 Takeda Pharmaceutical Im munde zerfallende tablette enthaltend ein benzimidazole
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
ES2347968T3 (es) 1998-07-28 2010-11-26 Takeda Pharmaceutical Company Limited Preparacion solida que se disgrega rapidamente.
US7041313B1 (en) 1998-08-12 2006-05-09 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU1907100A (en) * 1998-10-30 2000-05-22 Curators Of The University Of Missouri, The Omeprazole solution and method of using same
CA2347981C (fr) 1998-11-18 2010-05-04 Astrazeneca Ab Procede chimique ameliore, et formulation pharmaceutique
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
CA2376202C (fr) 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Preparation et forme galenique comprenant un compose actif acido-labile
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AU2001270304A1 (en) 2000-07-07 2002-01-21 The Administrators Of The Tulane Educational Fund Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
AU2002221939A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Rapidly disintegrating tablet comprising an acid-labile active ingredient
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
ES2366430T3 (es) 2001-06-20 2011-10-20 Takeda Pharmaceutical Company Limited Método para fabricar comprimidos.
JP5138856B2 (ja) * 2001-06-20 2013-02-06 武田薬品工業株式会社 錠剤の製造方法
MXPA04002891A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Composicion farmaceutica a base de pasta de azucar.
ES2392960T3 (es) 2001-10-17 2012-12-17 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
JP2006282677A (ja) * 2001-10-17 2006-10-19 Takeda Chem Ind Ltd 酸に不安定な薬物の高含量顆粒
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
US7125563B2 (en) 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US6902746B2 (en) * 2002-07-03 2005-06-07 Yung Shin Pharmaceutical Industrial Co., Ltd. Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
EP1594479A1 (fr) * 2003-01-31 2005-11-16 Ranbaxy Laboratories Limited Compositions orales stables de benzimidazole et leurs procedes de preparation
WO2004073654A2 (fr) * 2003-02-20 2004-09-02 Santarus, Inc. Liberation immediate d'un complexe antacide d'omeprazole presentant une nouvelle formulation pour une elimination rapide et prolongee d'acide gastrique
JP4891064B2 (ja) * 2003-02-24 2012-03-07 田辺三菱製薬株式会社 テナトプラゾールの光学異性体および治療におけるその使用
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
EP2112920B1 (fr) * 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
DE602004025113D1 (de) * 2003-07-11 2010-03-04 Astrazeneca Ab Feste zusammensetzung mit einem protonenpumpenhemmer
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1648416A4 (fr) * 2003-07-18 2012-03-28 Santarus Inc Formulations pharmaceutiques utilisees pour inhiber une secretion acide et procede de fabrication associe
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005123042A1 (fr) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Preparation pharmaceutique a liberation lente
CA2570916C (fr) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Forme posologique d'ipp a doses multiples
FR2871800B1 (fr) * 2004-06-17 2006-08-25 Sidem Pharma Sa Sa Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
WO2007075980A2 (fr) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Comprimes de lansoprazole se desintegrant oralement
EP1813275A1 (fr) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Comprime oral desintegrable de lansoprazole
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
MY151468A (en) * 2005-12-28 2014-05-30 Takeda Pharmaceutical Controlled release solid preparation
EP1965774A2 (fr) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Formulations pharmaceutiques à usage oral contenant des médicaments anti-inflammatoires non stéroïdiens et des inhibiteurs d'acides
EP2007360B1 (fr) * 2006-04-03 2014-11-26 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
LT2007362T (lt) * 2006-04-04 2018-11-26 Kg Acquisition Llc Geriamosios vaisto formos, apimančios prieštrombocitinį agentą ir rūgšties inhibitorių
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
WO2007122478A2 (fr) * 2006-04-20 2007-11-01 Themis Laboratories Private Limited Compositions à unités multiples
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
CN101500553B (zh) * 2006-07-25 2012-04-18 维克塔有限公司 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
BRPI0714915A2 (pt) * 2006-07-28 2013-05-28 Reddys Lab Ltd Dr composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TR200605624A2 (tr) * 2006-10-10 2008-05-21 Nobel İlaç Sanayi̇ Ve Ti̇caret Aş. Farmasötik dozaj şekli
CA2667682A1 (fr) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprenant des agents d'inhibition de la pompe a protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procedes d'utilisation
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
EP2044932A1 (fr) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Couche de protection mécanique pour formes de dosages solides
RU2010119041A (ru) 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
WO2009105568A1 (fr) 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprenant une combinaison d'oméprazole et de lansoprazole, et un agent tampon, et ses méthodes d'utilisation
GEP20135845B (en) 2008-03-11 2013-06-10 Takeda Pharmaceutical Orally-disintegrating solid formulation
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
WO2009137648A1 (fr) * 2008-05-09 2009-11-12 Aptapharma, Inc. Pastilles multicouches inhibant la pompe à protons
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2345408A3 (fr) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Formulations de médicament labiles acides
HUE026713T2 (en) 2010-02-25 2016-07-28 Evonik Roehm Gmbh A pharmaceutical composition or herbal preparation
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
US20130122090A1 (en) 2010-07-22 2013-05-16 Lupin Limited Multiple Unit Tablet Composition
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
EP2468263A1 (fr) * 2010-12-23 2012-06-27 Laboratorios Del. Dr. Esteve, S.A. Formes de dosage solides compressées
CN102805735A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 一种埃索美拉唑肠溶微丸片及其制备方法
CA2851327C (fr) * 2011-11-02 2019-06-25 Laboratorios Del Dr. Esteve, S.A. Granules d'omeprazole enrobees
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1545612A (fr) * 1967-06-15 1968-11-15 Dausse Lab Procédé de fabrication de comprimés
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
CA2083606C (fr) * 1990-06-20 2001-08-21 Arne Elof Brandstrom Derives de dialcoxypyridinylbenzimidazole; methode de preparation et utilisation en pharmacie
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
DE69430921T2 (de) * 1993-10-12 2003-02-13 Mitsubishi Pharma Corp., Osaka Darmlösliche grannulatkörner enthaltende tablette
DK0723436T3 (da) * 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation

Also Published As

Publication number Publication date
RU2166935C2 (ru) 2001-05-20
FI122016B (fi) 2011-07-29
CA2170995A1 (fr) 1996-01-26
MX9600856A (es) 1997-10-31
NO960948L (no) 1996-03-07
RU2538511C2 (ru) 2015-01-10
MY114388A (en) 2002-10-31
WO1996001625A1 (fr) 1996-01-25
IS4328A (is) 1996-03-04
NO960948D0 (no) 1996-03-07
ZA955546B (en) 1996-01-08
HU9600574D0 (en) 1996-05-28
HU9600572D0 (en) 1996-05-28
SK283841B6 (sk) 2004-03-02
CZ73096A3 (en) 1996-07-17
IL114447A (en) 2002-09-12
UA47390C2 (uk) 2002-07-15
IS4326A (is) 1996-03-04
AU2993895A (en) 1996-02-09
SK30096A3 (en) 1997-09-10
ATE275396T1 (de) 2004-09-15
CZ294380B6 (cs) 2004-12-15
PL180598B1 (pl) 2001-03-30
TR199500825A2 (tr) 1996-06-21
FI961059A (fi) 1996-03-07
IL114447A0 (en) 1995-11-27
JPH09502740A (ja) 1997-03-18
EP1452172A2 (fr) 2004-09-01
TNSN95076A1 (fr) 1996-02-06
EP1452172A3 (fr) 2004-11-03
CA2170644A1 (fr) 1996-01-25
NO316863B1 (no) 2004-06-07
IS4329A (is) 1996-03-04
CN1152671C (zh) 2004-06-09
NO960949D0 (no) 1996-03-07
EE03292B1 (et) 2000-10-16
HK1008298A1 (en) 1999-05-07
NO960949L (no) 1996-03-07
CN1134667A (zh) 1996-10-30
SE9402431D0 (sv) 1994-07-08
DE69533470T2 (de) 2005-09-22
ES2227556T3 (es) 2005-04-01
PL313389A1 (en) 1996-06-24
US5753265A (en) 1998-05-19
PT723437E (pt) 2004-12-31
DK0723437T3 (da) 2004-12-13
FI961058A (fi) 1996-03-07
CA2170644C (fr) 2011-02-22
CN1134668A (zh) 1996-10-30
JP3878669B2 (ja) 2007-02-07
AU695971B2 (en) 1998-08-27
WO1996001624A1 (fr) 1996-01-25
KR100384961B1 (ko) 2003-08-25
FI961059A0 (fi) 1996-03-07
EP0723437A1 (fr) 1996-07-31
IL114449A0 (en) 1995-11-27
SI0723437T1 (en) 2005-02-28
SA95160092B1 (ar) 2006-06-20
EP0724434A1 (fr) 1996-08-07
HUT75934A (en) 1997-05-28
ZA955547B (en) 1996-01-08
BR9506029A (pt) 1997-10-14
FI961058A0 (fi) 1996-03-07
NZ289949A (en) 1997-07-27
DE69533470D1 (de) 2004-10-14
TW421599B (en) 2001-02-11
EP0723437B1 (fr) 2004-09-08
BR9506028A (pt) 1997-10-14
PL313388A1 (en) 1996-06-24
JPH09502741A (ja) 1997-03-18
TR199500826A2 (tr) 1996-06-21

Similar Documents

Publication Publication Date Title
TNSN95076A1 (fr) Forme de dosage ii d'unite multiple en comprime
MY112915A (en) Multiple unit tableted dosage form 1
SE9500422D0 (sv) New oral pharmaceutical dosage forms
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
CA2214027A1 (fr) Formes galeniques effervescentes a unites multiples comprenant un inhibiteur de la pompe a protons
ES2145913T3 (es) Inhibidores de metaloproteasas.
ATE173923T1 (de) Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.
JO1881B1 (en) Formula II for multi unit disc calibration
JO1880B1 (en) Format 1 for multi-unit calibration discs
JO1821B1 (en) New pharmaceutical product
RS49796B (sr) UPOTREBA SOLI 3α, 7α-DIHIDROKSI-12-KETO-5β-HOLANSKE KISELINE KAO AKTIVNE SUPSTANCE ZA IZRADU LEKOVA ZA LEČENJE DIJABETESA